New England Research & Management Inc. Sells 16,274 Shares of Pfizer Inc. (NYSE:PFE)

New England Research & Management Inc. lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 21.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 58,189 shares of the biopharmaceutical company's stock after selling 16,274 shares during the quarter. New England Research & Management Inc.'s holdings in Pfizer were worth $1,544,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Swiss National Bank grew its stake in shares of Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after acquiring an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. Empowered Funds LLC raised its position in shares of Pfizer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after purchasing an additional 227,349 shares during the period. Addison Advisors LLC boosted its holdings in Pfizer by 394.2% in the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after buying an additional 41,668 shares during the period. Finally, KBC Group NV boosted its holdings in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock worth $89,872,000 after buying an additional 639,985 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.8 %

Shares of PFE stock traded up $0.22 during mid-day trading on Thursday, reaching $26.84. The stock had a trading volume of 18,391,473 shares, compared to its average volume of 35,047,313. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average price is $26.22 and its two-hundred day moving average price is $27.90. The firm has a market capitalization of $152.11 billion, a PE ratio of 36.30, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.17) EPS. Equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.41%. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is currently 227.03%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on PFE shares. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective for the company. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Guggenheim cut their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.